http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010019120-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c0d57266162f0324ccb5ed4b6fe25e42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a933a0dd561e3e50b278738704d5c6e6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e7b9f8bc98245b9c3c846ec99efacf9d |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P17-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-1709 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
filingDate | 2008-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8533ba3399666905884f8158aaf3b1e8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7a8b26119555a2b7bbced3ed69776ce5 |
publicationDate | 2010-02-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | WO-2010019120-A1 |
titleOfInvention | S0x9, prostaglandin d2 and retinoic acid for treating pigmentary conditions and melanoma |
abstract | A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to the subject an amount of inhibitor of SOX9 activity sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. A method of treating melanoma in a subject comprising increasing the amounts of retinoic acid and SOX9 in the subject by amounts sufficient to treat melanoma. A method of treating melanoma in a subject comprising administering to the subject an amount of prostaglandin D2 (PGD2) and retinoic acid (RA) sufficient to treat cancer. A method of sensitizing a melanoma cell to RA comprising administering to the subject an amount of SOX9 sufficient to decrease PRAME expression. A method of increasing p21 expression in a subject comprising administering to the subject an amount of SOX9 sufficient to increase p21 expression. Methods of screening for compounds that treat hypopigmentary conditions and/or melanoma are provided. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115786504-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-115786504-B http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11584967-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10612099-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021752-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2971156-A4 |
priorityDate | 2008-08-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 2623.